Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Feb. 28, 2017	Feb. 29, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (2,941,557)	$ (4,654,179)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	95,838	96,188
Share-based compensation	640,865	822,801
Accretion of debt discount included in interest expense	958,053	253,313
Loss on sale of notes receivable and assets	112,500	10,196
Loss on settlement of accounts payable	64,323	0
Loss on settlement of capital lease	0	8,820
Gain related to reimbursement of prior period research and development expense (Note 4)	0	(150,000)
Loss on extinguishment of debt	1,375,829	0
Change in fair value of warrant liability	(2,405,985)	(349,596)
Change in fair value of put option embedded in note payable	(614,484)	10,015
Net changes in assets and liabilities
Prepaid expenses	170,664	112,877
Refundable deposit	0	(3,600)
Accounts payable and accrued expenses	(50,095)	648,980
Deferred research and development reimbursement	177,517	0
Interest payable	101,889	53,649
Net Cash used in Operating Activities	(2,314,643)	(3,140,536)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from note receivable	0	100,000
Proceeds received from settlement of capital lease	0	2,897
Proceeds from sale of note receivable	12,500	0
Purchase of equipment	(13,421)	(151,830)
Net Cash used in Investing Activities	(921)	(48,933)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of debt	122,790	1,611,408
Proceeds from issuance of common stock and warrants, net	2,746,688	0
Proceeds from issuance of Series B preferred stock and warrant, net	0	1,945,244
Re-purchase of common stock and warrants	0	(111,563)
Payment of notes	(8,000)	0
Payment of capital lease obligation	0	(42,407)
Payment of short-term debt	(126,990)	(107,250)
Net Cash provided by Financing Activities	2,734,488	3,295,432
Net increase in cash and cash equivalents	418,924	105,963
Cash and cash equivalents at the beginning of the year	363,783	257,820
Cash and cash equivalents at the end of the year	782,707	363,783
Supplemental Disclosure of Non-Cash Financing Activities
Warrant liability associated with note payable	15,225	311,057
Placement agent warrants issued with note payable	0	16,800
Issuance of common stock and warrants as payment of accounts payable	212,278	0
Issuance of common stock and warrants to convert debt and accrued interest	2,326,321	0
Financing of insurance premium through notes payable	158,400	107,250
Note receivable received for sale of assets	0	75,000
Warrants issued to placement agents	278,223	175,241
Series B Preferred PIK dividend	191,941	235,508
Series B Preferred Stock accrued dividends	227,163	267,058
Capital lease settled against deposit	0	227,235
Deemed dividend related to Series B Preferred Stock BCF adjustment for conversion price adjustment	708,303	0
Issuance of common stock , preferred stock and warrants in exchange for cancellation of Series B preferred stock and Series A Warrants	67,900	0
Deemed dividend to Series B preferred stock holders upon exercising Most Favorable Nation option	2,340,552	0
Exchange OID notes and note payable to convertible debt	986,269	0
Issuance of warrants in connection with OID Notes amendment	$ 44,095	$ 0